NDA 020333 · Takeda Pharms USA
Agrylin
Anagrelide Hydrochloride · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Mar 14, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
24
11 Phase 3, 0 recruiting
FAERS reports
1,175
946 serious, 128 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 8, 2026.
AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )
Mechanism: The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 10, 2004 Supplement 8 · Efficacy · priority review LetterLabel
- Dec 16, 1998 Supplement 2 · Efficacy LabelReviewLetter
- Mar 14, 1997 Original approval · Type 1 - New Molecular Entity · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
2 products under this application
- AGRYLIN · ANAGRELIDE HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
- AGRYLIN · ANAGRELIDE HYDROCHLORIDE EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Anagrelide" as an intervention, any sponsor and status, largest first.
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06079879 · 340 participants (planned) · Start Dec 31, 2023 · Primary completion Jul 14, 2027
Drug: Bomedemstat; Anagrelide and 3 more · For: Essential Thrombocythemia
Sites: Glendale, Arizona; Glendale, California; Stanford, California · 161 sites in all
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT01243944 · 222 participants · Start Oct 27, 2010 · Primary completion Jan 15, 2014
Drug: ruxolitinib tablets · For: Polycythemia Vera
Sites: Birmingham, Alabama; Scottsdale, Arizona; Pomona, California · 102 sites in all
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaPivotal-lookingActive, not recruiting
RWTH Aachen UniversityAcademic, hospital or other
NCT02577926 · 207 participants · Start Oct 2015 · Primary completion Dec 2027
Drug: Ruxolitinib; BAT · For: Polycythemia Vera (PV); Essential Thrombocythemia (ET)
Sites: Mannheim, Germany; Ulm, Germany; Winnenden, Germany · 23 sites in all
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntolerancePivotal-lookingActive, not recruiting
PharmaEssentiaIndustry
NCT04285086 · 174 participants · Start Aug 25, 2020 · Primary completion Nov 12, 2024
Drug: Ropeginterferon alfa-2b; Anagrelide · For: Essential Thrombocythemia
Sites: Scottsdale, Arizona; St Louis, Missouri; Houston, Texas · 67 sites in all
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFPivotal-lookingCompleted
Sierra Oncology LLC - a GSK companyIndustry
NCT02101268 · 156 participants · Start Jun 19, 2014 · Primary completion Jul 28, 2016
Drug: Momelotinib; Best Available Therapy (BAT) · For: Primary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sites: Los Angeles, California; Gainesville, Florida; Atlanta, Georgia · 48 sites in all
- A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia PatientsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00202644 · 150 participants · Start Jan 13, 2006 · Primary completion Dec 15, 2015
Drug: Anagrelide; Hydroxyurea · For: Thrombocythemia, Hemorrhagic
Sites: Pleven, Bulgaria; Sofia, Bulgaria; Varna, Bulgaria · 15 sites in all
- Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02038036 · 149 participants · Start Mar 25, 2014 · Primary completion Sep 29, 2015
Drug: Best Available Therapy; Ruxolitinib · For: Polycythemia Vera
Sites: Herston, Australia; Antwerp, Belgium; Leuven, Belgium · 48 sites in all
- Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential ThrombocythaemiaPivotal-lookingCompleted
AOP Orphan Pharmaceuticals AGIndustry
NCT01230775 · 146 participants · Start Dec 2010 · Primary completion Jan 2015
Drug: Anagrelide retard; Placebo · For: Essential Thrombocythaemia
Sites: Innsbruck, Austria; Salzburg, Austria; Vienna, Austria · 37 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use82
- anaemia63
- platelet count increased60
- cerebral infarction51
- headache46
- fatigue45
- diarrhoea42
- dizziness41
- myelofibrosis41
- haemoglobin decreased38
- nausea36
- asthenia34
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 33 |
| 2005 | 42 |
| 2006 | 32 |
| 2007 | 22 |
| 2008 | 31 |
| 2009 | 18 |
| 2010 | 12 |
| 2011 | 58 |
| 2012 | 55 |
| 2013 | 17 |
| 2014 | 17 |
| 2015 | 34 |
| 2016 | 42 |
| 2017 | 72 |
| 2018 | 82 |
| 2019 | 105 |
| 2020 | 87 |
| 2021 | 80 |
| 2022 | 67 |
| 2023 | 100 |
| 2024 | 65 |
| 2025 | 66 |
| 2026 | 38 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Agrylin (Anagrelide HCl)
2024 spending
$159K
Beneficiaries
33
151 claims
Per beneficiary
$4,810
$7.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,931,961 |
| 2021 | $552,598 |
| 2022 | $336,322 |
| 2023 | $232,260 |
| 2024 | $158,726 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
Mesa R, Gill H, Zhang L, et al. · Lancet Haematol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Comparative Study
- Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Gotic M, Egyed M, Gercheva L, et al. · Cardiovasc Toxicol 2021 · Clinical Trial, Phase III, Comparative Study
- Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.
Abreu Lopez B, Arvelaez Pascucci J, Ramzy SM, et al. · Int J Hematol 2025 · Systematic Review, Meta-Analysis
- Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B, Chai-Adisaksopha C, Garcia D · J Thromb Thrombolysis 2015 · Comparative Study, Meta-Analysis
- Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
Laguna MS, Kornblihtt LI, Marta RF, et al. · Clin Appl Thromb Hemost 2000 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.